TREATMENT OF EOSINOPHILIC ESOPHAGITIS WITH OMALUZIMAB

用 Omaluzimab 治疗嗜酸性食管炎

• 批准号: 7718515
• 负责人: JOHN FANG
• 金额: $ 0.34万
• 依托单位: UNIVERSITY OF UTAH
• 依托单位国家: 美国
• 财政年份: 2008
• 资助国家: 美国
• 起止时间: 2008-03-01 至 2008-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7718515
• 关键词: Acute; Adrenal Cortex Hormones; Adverse effects; Allergens; Allergic; Allergic rhinitis; Antibodies; Asthma; Atopic Dermatitis; Breathing; Child; Computer Retrieval of Information on Scientific Projects Database; Condition; Conjunctivitis; Cromolyn Sodium; Deglutition Disorders; Diet; Disease; Effectiveness; Eosinophilic Esophagitis; Epidemic; Esophageal; Extrinsic asthma; Family history of; Food; Food Hypersensitivity; Frequencies; Functional disorder; Funding; Grant; Hypersensitivity; IgE; Immune; Immune response; Incidence; Inflammation; Inflammatory Response; Institution; Mediating; Modeling; Oral; Patients; Research; Research Personnel; Resources; Source; Steroids; Symptoms; Therapeutic; Topical Corticosteroids; United States National Institutes of Health; anti-IgE; atopy; eosinophil; improved; omalizumab; young adult

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Eosinophilic Esophagitis (EE) is an increasingly recognized condition characterized by dysphagia, food impaction or other obstructive esophageal symptoms in children and young adults. The pathophysiology of EE appears to be an allergy/atopy mediated disease. A personal and family history of allergic diseases (food allergies, atopic dermatitis, asthma, allergic rhinitis or conjunctivitis) has been noted in 62-85% of patients with EE. The rising incidence of EE may be related to the worldwide allergy and asthma epidemic. Current treatment of EE is directed at decreasing esophageal allergic inflammation. Oral and topical corticosteroids, cromolyn sodium, monoleukast and elemental/elimination diets have all been shown to be effective. However, none of these treatments are directed at the specific pathophysiologic mechanism of EE and some have significant side effects. The shared pathogenetic mechanisms of EE and asthma suggest that therapeutic strategies directed at asthma may also be effective for EE. Specifically those targeted at the allergic immune mechanisms involved with asthma may be effective. Omalizumab is a recently developed anti-IgE antibody that has been shown to decrease the use of inhaled and oral corticosteroids, reduce the frequency of asthma exacerbations, and improve asthma related symptoms in patients with allergic asthma. In addition, by its ability to lower free circulating IgE levels, omalizumab inhibits the immune response to many different allergens. This information suggests that omalizumab may be an ideal therapy for EE where the specific allergens are seldom known and steroid treatment merely suppresses the acute inflammatory response without altering the unerlying pathogenetic mechanism of the disease. Demonstration of omalizumab effectiveness in EE may serve as a model for other eosinophil associated diseases.

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 嗜酸性粒细胞性食管炎（EE）是一种日益被认可的疾病，其特征是吞咽困难，食物嵌塞或儿童和年轻人的其他阻塞性食管症状。 EE的病理生理学似乎是过敏/特应性介导的疾病。在62-85%的EE患者中发现了过敏性疾病（食物过敏、特应性皮炎、哮喘、过敏性鼻炎或结膜炎）的个人和家族史。EE发病率的上升可能与全球范围内的过敏和哮喘流行有关。 目前EE的治疗是针对减少食管过敏性炎症。口服和外用皮质类固醇、克罗埃因钠、单白司特和元素/消除饮食均已被证明有效。然而，这些治疗都不是针对EE的特定病理生理机制，有些治疗具有显著的副作用。 EE和哮喘的共同发病机制表明，针对哮喘的治疗策略也可能对EE有效。特别是针对与哮喘相关的过敏性免疫机制的治疗策略可能有效。奥马珠单抗是最近开发的一种抗IgE抗体，已被证明可减少吸入和口服皮质类固醇的使用，降低哮喘急性发作的频率，并改善过敏性哮喘患者的哮喘相关症状。此外，奥马珠单抗通过降低游离循环IgE水平的能力，抑制对许多不同过敏原的免疫应答。这一信息表明，奥马珠单抗可能是一种理想的治疗EE的特定过敏原是很少知道和类固醇治疗只是抑制急性炎症反应，而不改变疾病的unerlying发病机制。奥马珠单抗在EE中的有效性的证明可以作为其他嗜酸性粒细胞相关疾病的模型。